Contact:

Douglas Doerfler
Chief Executive Officer
MaxCyte, Inc.
(301) 944-1700

For Immediate Release

MaxCyte appoints Madhusudan V. Peshwa, Ph.D.

As Vice President Research and Development

Gaithersburg, MD, March 21, 2005 – MaxCyte, Inc., a clinical stage therapeutic company and pioneer in clinical scale, non-viral cell loading technologies, announced today that it has appointed Madhusudan V Peshwa, Ph.D. as Vice President, Research and Development.

Douglas A Doerfler, President and CEO of MaxCyte commented, "We are extremely excited that Peshwa has joined MaxCyte as he brings solid technical and commercial skills. His experience in delivering cell-based biologic products from concept through translational development and scale-up to commercial implementation will be a valuable addition to the MaxCyte team."

"MaxCyte's clinical, non-viral cell loading and gene delivery technology system is scalable, robust and provides high yields for therapeutic development and biopharmaceutical production applications," said Dr. Peshwa. "I am excited to combine my product development experiences with MaxCyte's technology to advance our partners' and our own proprietary therapeutic products."

Prior to joining MaxCyte, Dr Peshwa was Executive Vice President, Research and Development at NewNeural LLC, a regenerative medicine company. Previously, he held positions as Vice President, Manufacturing and as Vice President, Process Sciences at Dendreon Corporation (NASDAQ:DNDN) a developer of cancer vaccines. Dr Peshwa holds a PhD in Chemical Engineering from the University of Minnesota.

About MaxCyte

MaxCyte is a clinical stage therapeutics company developing both proprietary and partnered therapeutics. The company's mission is to use its proprietary cell-loading technology to advance its therapeutic programs and enable other developers of ex vivo cell therapies and manufacturers of biopharmaceutical products and therapies. MaxCyte's strength is its ability to accelerate development timelines and reduce risk in bringing cell and gene therapies from bench to a clinical reality. MaxCyte's proprietary cell loading technology is closed and scalable, highly efficient, reproducible and reduces regulatory risk in *ex vivo* cell loading. MaxCyte's pipeline includes one product in Phase I/II clinical trials for the treatment of Chronic Lymphocytic Leukemia (CLL) and several preclinical candidates to treat a variety of diseases with unmet needs. Therapeutic applications include non-viral gene delivery and delivery of a therapeutic drug or large proteins; current partners are working to develop therapeutics for pulmonary disease and oncology. MaxCyte's technology for biotherapeutic manufacturing allows the scalable production of viral vectors, making possible all phases of the development process, from pre-clinical through clinical

trials and through to product manufacturing. Cell-loading technologies are fundamental to cell-based therapeutics, gene therapy, and many biopharmaceutical manufacturing applications. MaxCyte has developed and commercialized the most efficient non-viral, clinical grade, scaleable, GMP-compliant cell-loading technology in the marketplace.

For more information including the referenced abstract, visit http://www.maxcyte.com.

This press release may contain, in addition to historical information, certain forward-looking statements that involve risks and uncertainties. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including risks and uncertainties.

###